Table 2

Multivariate analysis for progression-free and overall survival

EndpointSubgroupNHR95% CIP value
PFSPD-L1 status (TPS ≥1)n 110Embedded Image0.54(0.33 to 0.87)0.012
Stromal CD8+ (>697)0.59(0.34 to 1.01)0.055
Sex (male)0.87(0.54 to 1.39)0.560
Age (>62)1.04(0.65 to 1.65)0.868
Intratumoral CD163+ (>472 cells/mm2)1.80(1.10 to 2.93)0.019
Previous treatment line (>1)1.82(1.05 to 3.15)0.034
Performance status (>1)1.96(1.07 to 3.59)0.030
OSPD-L1 status (TPS ≥1)110Embedded Image0.50(0.27 to 0.92)0.027
Stromal CD8+ (>697)0.68(0.36 to 1.28)0.233
Sex (male)0.72(0.41 to 1.29)0.276
Age (>62)1.33(0.77 to 2.31)0.308
Previous treatment line (>1)2.05(1.10 to 3.80)0.023
Intratumoral CD163+ (>472 cells/mm2)2.69(1.45 to 4.99)0.002
Performance status (>1)3.82(1.92 to 7.60)<0.001
  • OS, overall survival; PD-L1, programmed cell death ligand 1; PFS, progression -free survival; TPS, tumor proportion score .